The salt and chlorine activities of Nouryon, the former specialty chemical branch of AkzoNobel, may be marketed independently. CEO Charlie Shaver said so in an interview with Bloomberg news agency in London.

Carlyle shareholder, who invested the company for more than 10 billion euros last year, is currently investigating whether such a spin-off and IPO would be interesting. The remaining activities of Nouryon could be brought to the stock exchange later than also. Carlyle is also looking at several options.

It is not the first time that a possible return to the Nouryon stock exchange has been discussed. Immediately after completion of the acquisition by Carlyle, Shaver stated that it is obvious that the company could be brought back to the stock market in three to five years. That would probably happen in the United States, he said at the time.